To Set up NTM Stimulation Test Foar Diagnosing NTM Pulmonary Infectionon.NCT01676142
Establishing a Diagnostic Test for Non-tuberculous Mycobacteria Lung Infection Using Non-tuberculous Mycobacteria Antigen Stimulation Test: From Immune Base, Standardized Setup to Validation
An observational study of To Set up NTM Stimulation Test Foar Diagnosing NTM Pulmonary Infectionon., run by National Taiwan University Hospital at 1 site in Taiwan.
Trial summary
1. To compare TLR-2 expression of peripheral blood mononuclear cells and serum downstream cytokines in those with MAC or MAB pulmonary infection and those with MAC or MAB pulmonary colonization and controls. 2. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- To Set up NTM Stimulation Test Foar Diagnosing NTM Pulmonary Infectionon.
- How many people
- 200 participants
- Where
- 1 siteTaiwan
- Study dates
- Jan 2011to Jan 2014
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: 1. Patients with NTM pulmonary infection: diagnosed by NTM guidelines by American Thoracic Society(ATS) 2. Patients with NTM pulmonary colonization: Patients are not fulfilling the ATS diagnostic criteria but having at least one set of positive sputum for NTM (colonization). 3. Patients have pulmonary infiltrates, not related by NTM: three sets of respiratory specimens that are negative for NTM.
Who may be able to join
- Age ≥ 18 years
- A patient has at least 3 sets of respiratory specimen for mycobacterial culture.
Who cannot join
- Age younger than 18 years.
- Patients who have pregnancy.
- Patients who have acquired immunodeficiency syndrome
- Patients who have bleeding tendency which can not tolerate venous puncture such as hemophilia, thrombocytopenia.
- In NTM infection group, patients having received anti-NTM treatment for one week will be excluded.
Trial locations and contacts
1 site in 1 country.
Taiwan1 site, 1 recruiting
- Recruiting
National Taiwan University Hospital
Taipei, 100
Chin-Chung Shu, MD, 886972653087
Chin-Chung Shu, MD
About this study
- To compare TLR-2 expression of peripheral blood mononuclear cells and serum downstream cytokines in those with MAC or MAB pulmonary infection and those with MAC or MAB pulmonary colonization and controls.
- To investigate the response of TLR-2 expression and cytokines activation to NTM stimulation test in patients with MAC or MAB pulmonary infection and colonization and controls.
- To validate the NTM stimulation test for NTM pulmonary infection.
Read the detailed description
The increase of nontuberculous mycobacteria lung infection Nontuberculous mycobacteria lung infection (NTM-LD) becomes an important clinical concern [1] because the rate of NTM infection has increased over the past ten years [2-3]. According to a study in Taiwan, NTM-LD increased from 1.26 to 7.94 per 100,000 inpatients/year during 2000 to 2008 [2]. The reasons for this increase are not readily clear, but could be related to the growth in numbers of the acquired immunocompromised population and advances of technique for mycobacterial culture [4-7]. Among the NTM infection in Taiwan, Mycobacterium avium complex (MAC) and M. abscessus (MAB) were most frequently isolated [2].
The difficulty in early diagnosing and confirming true NTM-LD However, NTM exists in the environment ubiquitously, so the relevance (true disease patient number over the number of patients with disease or just colonization) is far less than 100% and varied in different NTM species. For example, previous studies have shown that the presence of M. kansasii and MAC had a clinical relevance around 47~70% and 35~42%, respectively [8-9]. As for MAB which is emerging pathogen worldwide, has a relevance of 33% [9]. According to contemporary NTM guidelines established by American thoracic society, NTM pulmonary infection is diagnosed by multiple criteria including microbiology of respiratory specimen and clinical findings as well as radiographic findings [1]. In microbiology criteria, two or more sets of positive sputum mycobacterial culture for the same NTM species within one year is needed.
Because NTM colonization is not uncommon in respiratory tract, diagnosis of true pulmonary NTM infection is a great challenge in clinical practice. Actually, microbiology tests for mycobacteria are neither timely nor efficient. Mycobacterial culture is time-consuming, which needed weeks to wait the results even though it's current gold standard for micro-organism identification [10]. The nucleic acid amplification method such as polymerase chain reaction could not discriminate true NTM infection and solely colonization because the micro-organism is present in both situations [11].
To early diagnose and then start treatment of NTM infection is important because NTM pulmonary infection might be rapid lethal infection in intensive care unit or in patients who had not received early proper treatment [6]. In addition, MAC or MAB which are most common in Taiwan are resistant to most of anti-tuberculosis regimen. Hence, more rapid and accurate diagnostic test should be developed [1-2, 6] The help of innate immunity in diagnosing NTM-LD The body inflammatory marker, represent our immune response, would be an indicator for differentiating true mycobacterial pulmonary infection from colonization while the first set of mycobacterial culture grew NTM [12-15]. Both interferon-gamma and tumor necrosis factor-alpha play critical roles in protective immunity to mycobacterial infections [16-17]. These responses are linked to engagement of Toll-like receptor 2 (TLR2) that is critical for mycobacterial infection [18]. However, the TLR-2 expression has not been evaluated between patients with NTM infection and colonization. According to the success of application of interferon-gamma release assay for tuberculosis detection [19], we understand the specific immune response is helpful to diagnose mycobacterial infection. We therefore focus on the expression of TLR-2 and associated downstream cytokines in our patients with MAC or MAB lung disease, which accounts the most of NTM infection [2].
The design in our study for diagnosis In order to investigate the help of host immune in diagnosing NTM pulmonary infection, we initially compare the baseline expression of TLR-2 and downstream cytokines in the MAC or MAB infected patients and colonized subjects. Then, we perform an in-vitro stimulation test using mycobacteria (MAC or MAB) for co-culturing with peripheral blood mononuclear cells of patients. The TLR-2 expression and cytokines activation will be examined after the stimulation test. We then analyze the expression difference between NTM-LD and colonization.
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Patients with NTM pulmonary infection | Not described | |
| Patients with other pathogen related lung infection | Not described | |
| Patient with NTM pulmonary colonization | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
Patients with non-tuberculous pulmonary infection
Measured: 3 year
Secondary outcomes (1)
mortality
Measured: 3 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Aug 2012 (estimated)
- Study startJan 2011
- Primary completionJan 2014 (estimated)
- Study completionJan 2014 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for To Set up NTM Stimulation Test Foar Diagnosing NTM Pulmonary Infectionon.Studies of the same condition, open and under way.
- More trials run by National Taiwan University HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- National Taiwan University Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Chin-Chung Shu, MD, Principal investigator, National Taiwan University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01676142
- Sponsor's protocol ID
- 201012082RC
- Status last verified
- Jun 2011
- First submitted
- 28 Aug 2012
- Last updated
- 30 Aug 2012
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 30 Aug 2012. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Establishing a Diagnostic Test for Non-tuberculous Mycobacteria Lung Infection Using Non-tuberculous Mycobacteria Antigen Stimulation Test: From Immune Base, Standardized Setup to Validation
- ClinicalTrials.gov ID
- NCT01676142
- Acronym / sponsor ID
- 201012082RC
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 200 participants (estimated)
- Lead sponsor
- National Taiwan University HospitalUniversity, hospital or other
- Study start
- Jan 2011
- Primary completion
- Jan 2014 (estimated)
- Study completion
- Jan 2014 (estimated)
- First posted
- 30 Aug 2012 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
- To compare TLR-2 expression of peripheral blood mononuclear cells and serum downstream cytokines in those with MAC or MAB pulmonary infection and those with MAC or MAB pulmonary colonization and controls.
- To investigate the response of TLR-2 expression and cytokines activation to NTM stimulation test in patients with MAC or MAB pulmonary infection and colonization and controls.
- To validate the NTM stimulation test for NTM pulmonary infection.
Detailed description
The increase of nontuberculous mycobacteria lung infection Nontuberculous mycobacteria lung infection (NTM-LD) becomes an important clinical concern [1] because the rate of NTM infection has increased over the past ten years [2-3]. According to a study in Taiwan, NTM-LD increased from 1.26 to 7.94 per 100,000 inpatients/year during 2000 to 2008 [2]. The reasons for this increase are not readily clear, but could be related to the growth in numbers of the acquired immunocompromised population and advances of technique for mycobacterial culture [4-7]. Among the NTM infection in Taiwan, Mycobacterium avium complex (MAC) and M. abscessus (MAB) were most frequently isolated [2].
The difficulty in early diagnosing and confirming true NTM-LD However, NTM exists in the environment ubiquitously, so the relevance (true disease patient number over the number of patients with disease or just colonization) is far less than 100% and varied in different NTM species. For example, previous studies have shown that the presence of M. kansasii and MAC had a clinical relevance around 47~70% and 35~42%, respectively [8-9]. As for MAB which is emerging pathogen worldwide, has a relevance of 33% [9]. According to contemporary NTM guidelines established by American thoracic society, NTM pulmonary infection is diagnosed by multiple criteria including microbiology of respiratory specimen and clinical findings as well as radiographic findings [1]. In microbiology criteria, two or more sets of positive sputum mycobacterial culture for the same NTM species within one year is needed.
Because NTM colonization is not uncommon in respiratory tract, diagnosis of true pulmonary NTM infection is a great challenge in clinical practice. Actually, microbiology tests for mycobacteria are neither timely nor efficient. Mycobacterial culture is time-consuming, which needed weeks to wait the results even though it's current gold standard for micro-organism identification [10]. The nucleic acid amplification method such as polymerase chain reaction could not discriminate true NTM infection and solely colonization because the micro-organism is present in both situations [11].
To early diagnose and then start treatment of NTM infection is important because NTM pulmonary infection might be rapid lethal infection in intensive care unit or in patients who had not received early proper treatment [6]. In addition, MAC or MAB which are most common in Taiwan are resistant to most of anti-tuberculosis regimen. Hence, more rapid and accurate diagnostic test should be developed [1-2, 6] The help of innate immunity in diagnosing NTM-LD The body inflammatory marker, represent our immune response, would be an indicator for differentiating true mycobacterial pulmonary infection from colonization while the first set of mycobacterial culture grew NTM [12-15]. Both interferon-gamma and tumor necrosis factor-alpha play critical roles in protective immunity to mycobacterial infections [16-17]. These responses are linked to engagement of Toll-like receptor 2 (TLR2) that is critical for mycobacterial infection [18]. However, the TLR-2 expression has not been evaluated between patients with NTM infection and colonization. According to the success of application of interferon-gamma release assay for tuberculosis detection [19], we understand the specific immune response is helpful to diagnose mycobacterial infection. We therefore focus on the expression of TLR-2 and associated downstream cytokines in our patients with MAC or MAB lung disease, which accounts the most of NTM infection [2].
The design in our study for diagnosis In order to investigate the help of host immune in diagnosing NTM pulmonary infection, we initially compare the baseline expression of TLR-2 and downstream cytokines in the MAC or MAB infected patients and colonized subjects. Then, we perform an in-vitro stimulation test using mycobacteria (MAC or MAB) for co-culturing with peripheral blood mononuclear cells of patients. The TLR-2 expression and cytokines activation will be examined after the stimulation test. We then analyze the expression difference between NTM-LD and colonization.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Patients with NTM pulmonary infection | – | – |
| Patients with other pathogen related lung infection | – | – |
| Patient with NTM pulmonary colonization | – | – |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- 1. Patients with NTM pulmonary infection: diagnosed by NTM guidelines by American Thoracic Society(ATS) 2. Patients with NTM pulmonary colonization: Patients are not fulfilling the ATS diagnostic criteria but having at least one set of positive sputum for NTM (colonization). 3. Patients have pulmonary infiltrates, not related by NTM: three sets of respiratory specimens that are negative for NTM.
Key inclusion criteria (2 listed)
- Age ≥ 18 years
- A patient has at least 3 sets of respiratory specimen for mycobacterial culture.
Key exclusion criteria (5 listed)
- Age younger than 18 years.
- Patients who have pregnancy.
- Patients who have acquired immunodeficiency syndrome
- Patients who have bleeding tendency which can not tolerate venous puncture such as hemophilia, thrombocytopenia.
- In NTM infection group, patients having received anti-NTM treatment for one week will be excluded.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Patients with non-tuberculous pulmonary infection
Time frame: 3 year
1 secondary outcome
mortality
Time frame: 3 years
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Aug 2012.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Chin-Chung Shu, MD principal investigator
National Taiwan University Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of To Set up NTM Stimulation Test Foar Diagnosing NTM Pulmonary Infectionon., run by National Taiwan University Hospital at 1 site in Taiwan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 30 Aug 2012. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Chin-Chung Shu, MD (886972653087, chinchungshu@ntu.edu.tw), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Patients with non-tuberculous pulmonary infection (time frame: 3 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Aug 2012.